Combination therapy with gemcitabine in non-small cell lung cancer

The nucleoside analogue, gemcitabine, has shown activity as a single agent in the treatment of metastatic non-small cell lung cancer (NSCLC), producing consistent response rates of 20% and above. Because of its unique mechanism of action and its non-overlapping toxicity with other active agents, gemcitabine is an attractive candidate for trials in combination with other cytotoxic agents. in preclinical models, the cisplatin-gemcitabine combination suggested synergy between the two drugs. In phase I-II studies, response rates are as high as 54% when gemcitabine is combined with cisplatin, both in stage III and IV NSCLC. The combination of gemcitabine and ifosfamide is also being explored with an overall response rate of 32%. The gemcitabine-containing regimens showed a favourable safety-efficacy profile and compared well with standard regimens used in NSCLC. These preliminary results must be validated by large randomised trials comparing gemcitabine-containing regimens with NSCLC reference chemotherapy regimens. (C) 1997 Elsevier Science Ltd.